Angiogenesis and BPC-157: Healing Mechanism

Healing any injury starts with one thing: getting blood to the damaged area. Without blood supply, there's no oxygen, no nutrients, no immune cells. BPC-157 accelerates exactly this process through angiogenesis, the growth of new blood vessels.

What angiogenesis is

Angiogenesis is the formation of new capillaries from existing vessels. Driven primarily by VEGF (Vascular Endothelial Growth Factor). When tissue is damaged, cells in the injury zone release VEGF, which attracts endothelial cells to build new vessels toward the damage site.

BPC-157 and VEGF

[[BPC-157|22]] upregulates VEGF expression in damaged tissues. In a 2010 study on transected rat Achilles tendons, accelerated angiogenesis was observed by day 4 after BPC-157 administration. New vessels appeared faster than controls, providing early blood supply to the repair zone.

This mechanism explains why BPC-157 works across such different injuries: gut, tendons, muscles, nerves. All these tissues need blood for repair. BPC-157 ensures delivery.

Beyond VEGF

BPC-157 also modulates the nitric oxide system (affects vascular tone and blood flow) and stimulates EGF and FGF growth factors (epithelial and connective tissue repair). This isn't a single-pathway peptide. It coordinates multiple repair processes, with VEGF-driven angiogenesis as the centerpiece.

Practical significance

Injecting BPC-157 near the injury (250-500mcg/day subQ) provides locally high concentration of the VEGF stimulator exactly where new vessels are needed. That's why near-site injection is recommended over systemic.

[[BPC-157|22]] in 5mg and 10mg vials. For a broader repair approach, see [[GLOW|23]] (BPC-157 + TB-500 + GHK-Cu).

Questions? Reach out.

This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.